In sort of a preview of IBD's year-end special report, IBD scanned for 2023's best-performing stocks priced at $12 or higher that trade at least 100,000 shares a day on average. Reata Pharmaceuticals has gained an outstanding 345% this year through Friday. Shares catapulted 54% on July 28 alone, on news that Biogen entered into an agreement to acquire Reata for $172.50 per share in cash.